Fig. 1

Safety and functional recovery on hDPSC-treated mdx mice. a Schematic representation of the repeat or single hDPSC-treatment schedule in mdx mice. b Growth curve of 9 to 30-week-old wild type (WT), mdx, and hDPSC-treated mdx mice (n = 4 each). c Normalized grip strength (g/g body weight, BW) measured in 9-week-old WT (n = 6), untreated mdx (n = 9), repeat (n = 17, 7), and single (n = 3, 7) hDPSC (high- or low-dose)-treated mdx mice. d Quantification of maximum running speed (m/min) in the wheel cage, and e daily distance covered during wheel running in 12-week-old WT (n = 6–8), untreated mdx (n = 10–12), repeat (n = 8–9, 5–6), and single (n = 3, 6) hDPSC (high- or low-dose)-treated mdx mice. f Quantification of maximum running speed (m/min) in the wheel cage in 50-week-old mdx (n = 16–19), repeat hDPSC (high- or low-dose)-treated mdx mice (n = 13–14, 5). All data are represented as mean ± SD and statistical differences compared to WT (^*P < 0.05, ^****P < 0.0001) and untreated mdx (^#P < 0.05, ^##P < 0.01, and ^###P < 0.0005), one-way ANOVA